. 2016 Oct 11;6:34631. doi: 10.1038/srep34631

Table 2. Basic parameters in subgroups.

	Group 1 (n = 16) Before IVI	Group 2 (n = 15) Post-IVI ≤ 5 weeks	Group 3 (n = 15) Post-IVI > 5 weeks	P-value
	Group 1 (n = 16) Before IVI	Group 2 (n = 15) Post-IVI ≤ 5 weeks	Group 3 (n = 15) Post-IVI > 5 weeks	1 vs 2	1 vs 3	2 vs 3
Age (mean ± SD)	79.63 ± 7.88	75.33 ± 8.38	76.47 ± 10.35	0.15	0.34	0.74^a
Female/male	4/12	6/9	4/11	0.46	1.00	0.70^b
Latest IVI avastin/lucentis	not applicable	9/6	11/4	—	—	0.70^a
AMD/myopic NV/PCV	15/0/1	12/2/1	14/0/1	0.33	1.00	0.60^a
Follow-up months (mean ± SD)	14.38 ± 6.89	12.14 ± 6.67	18.00 ± 11.30	0.37	0.29	0.09^a
No. of samples below detection limit of VEGF after IVI	0	9 (60%)	2 (13.3%)	—	—	< 0.05^*^b

^aKruskal-Wallis test.

^bFisher’s two-tailed test.

IVI = intravitreal injection, AMD = age-related macular degeneration, NV = neovascularization, PCV = polypoidal choroidal vasculopathy, VEGF = vascular endothelial growth factor, SD = standard deviation.